Literature DB >> 19476049

Allergic conjunctivitis and H1 antihistamines.

A del Cuvillo1, J Sastre, J Montoro, I Jáuregui, I Dávila, M Ferrer, J Bartra, J Mullol, A Valero.   

Abstract

Allergic conjunctivitis is the most common form of ophthalmological allergy. Eye symptoms are one of the main and most frequent reasons for consultation among patients with allergic rhinoconjunctivitis, which in turn is the most common reason for visiting the allergologist, according to the Alergológica 2005 study. Itching is the key symptom of allergic conjunctivitis, and its relief is the principal objective of the broad range of treatment options available. Topical antihistamines with multiple actions (mast cell stabilization, and antiinflammatory and antihistaminic actions) are probably the best treatment option, thanks to their rapid action, safety and convenience of use. However, oral antihistamines (preferentially second generation drugs) can also play an important role, since they are of established efficacy and offer adequate treatment of the nasal symptoms that tend to accompany the ocular manifestations of allergic rhinoconjunctivitis. Models of allergic conjunctivitis are useful for investigational purposes and for advancing our knowledge of allergic reactions. Advances in the study of the physiopathology of ocular allergy allow us to introduce new therapeutic options for the management of such allergic reactions, thanks to the findings derived from models of this kind. The present review provides an update to the published data on allergic conjunctivitis and the current role of both topical and ocular antihistamines in treating the disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476049

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  8 in total

1.  Role of histamine and its receptor subtypes in stimulation of conjunctival goblet cell secretion.

Authors:  Densen Hayashi; Dayu Li; Chisato Hayashi; Marie Shatos; Robin R Hodges; Darlene A Dartt
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

2.  Formulation and Pathohistological Study of Mizolastine-Solid Lipid Nanoparticles-Loaded Ocular Hydrogels.

Authors:  Ghada Ahmed El-Emam; Germeen N S Girgis; Mohammed Fawzy Hamed; Osama Abd El-Azeem Soliman; Abd El Gawad H Abd El Gawad
Journal:  Int J Nanomedicine       Date:  2021-11-24

Review 3.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

4.  Maresin 1, a specialized proresolving mediator, stimulates intracellular [Ca2+ ] and secretion in conjunctival goblet cells.

Authors:  Markus V Olsen; Anne V Lyngstadaas; Jeffrey A Bair; Robin R Hodges; Tor P Utheim; Charles N Serhan; Darlene A Dartt
Journal:  J Cell Physiol       Date:  2020-06-08       Impact factor: 6.384

5.  Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.

Authors:  Gail Torkildsen; Abhijit Narvekar; Mark Bergmann
Journal:  Clin Ophthalmol       Date:  2015-09-14

6.  Retrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese.

Authors:  Macy M S Wu; Gordon S K Yau; Jacky W Y Lee; Amy L Wong; Victor T Y Tam; Can Y F Yuen
Journal:  ScientificWorldJournal       Date:  2014-10-15

7.  Levocetirizine inhibits migration of immune cells to lymph nodes and induces treg cells in a murine type I allergic conjunctivitis model.

Authors:  Sihomara García-Zepeda; Elizabet Estrada-Muñiz; Guillermo Elizondo; Luis I Terrazas; Miriam Rodríguez-Sosa; Juan D Quintana-Hau; Rubén Tornero-Montaño; Leopoldo Baiza-Durán; Libia Vega
Journal:  Open Ophthalmol J       Date:  2012-12-14

Review 8.  Potential Biomarkers for Allergic Conjunctival Diseases.

Authors:  Neeta Roy; Shir Levanon; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2020-03       Impact factor: 3.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.